TY - JOUR
T1 - 2024 Thai Rheumatism Association Guideline for the Treatment of Axial Spondyloarthritis with Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs
AU - on behalf of the Thai Rheumatism Association
AU - Katchamart, Wanruchada
AU - Aiewruengsurat, Duangkamol
AU - Chaiamnuay, Sumapa
AU - Chiowchanwisawakit, Praveena
AU - Jatuworapruk, Kanon
AU - Kasitanon, Nuntana
AU - Leosuthamas, Pornsawan
AU - Mahakkanukrauh, Ajanee
AU - Ngamjanyaporn, Pintip
AU - Orawongpaisarn, Annop
AU - Pakchotanon, Rattapol
AU - Pongkulkiat, Patnarin
AU - Uea-Areewongsa, Parichat
AU - Chevaisrakul, Parawee
AU - Pisitkun, Prapaporn
AU - Siriwattanakul, Suphawan
AU - Subphachaisirikul, Aungkarat
AU - Assawasaksakul, Theerada
AU - Louthrenoo, Worawit
AU - Goo, Phonpen Akarawatcharangura
AU - Kitumnuayong, Tasanee
AU - Ruksasakul, Rungkan
AU - Srivorrapattararkul, Sittikorn
AU - Khampaen, Tinh
AU - Wangkaew, Suparaporn
AU - O-Charoen, Pichaya
AU - Surabhakul, Neeracha
AU - Phumethum, Veerapong
AU - Suesuwan, Anawat
AU - Malaisri, Patariya
AU - Manavathongchai, Siriporn
AU - Hanvivadhanakul, Punchong
AU - Ussavasodhi, Prapassorn
AU - Koolvisoot, Ajchara
AU - Tantiwong, Pimchanok
AU - Onchan, Tippawan
AU - Panichaporn, Saranya
AU - Narongroeknawin, Pongthorn
AU - Asavatanabodee, Paijit
AU - Nanagara, Ratanavadee
AU - Phutthinart, Nattharadee
AU - Juthong, Siriporn
AU - Siripaitoon, Boonjing
AU - Pinyopornpanit, Virat
AU - Angthararak, Sungchai
N1 - Publisher Copyright:
© 2024 JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND.
PY - 2024/11
Y1 - 2024/11
N2 - Objective: To provide rheumatologists with the decisions for the appropriate and standardized treatment of patients with axial spondyloarthritis (axSpA) with biologic disease-modifying antirheumatic drugs (bDMARD) and targeted synthetic DMARDs (tsDMARD), according to current evidence and expert opinion. Materials and Methods: The development process involved 46 rheumatologist representatives from medical schools, government hospitals, and private hospitals nationwide. Relevant clinical questions related to treatment initiation criteria, administration, evaluation, monitoring, and intensive treatment options were selected. The evidence was systematically identified and summarized. Quality of evidence was evaluated and ranked according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) scoring methodology. The recommendations were then proposed and voted on using the nominal group process. The input was collected from stakeholders through a public hearing. The final 13 recommendations were provided. Results: The guideline addresses the criteria for starting bDMARD/tsDMARD and details the first-line drugs for specific disease profiles, including predominantly axial involvement, predominantly peripheral joint involvement, and uveitis. It also addresses the management of patients with comorbid conditions such as tuberculosis, chronic hepatitis B, malignancy, and pregnancy. Additionally, it covers monitoring and follow-up procedures, alternative treatments for first-line treatment failures, tapering treatment after remission, and reinstitution of bDMARD/tsDMARD in case of flare-up. Conclusion: Thai Rheumatism Association has proposed a set of recommendations to outline concepts and provide guidance on the treatment of axSpA with bDMARD and tsDMARD for Thai rheumatologists.
AB - Objective: To provide rheumatologists with the decisions for the appropriate and standardized treatment of patients with axial spondyloarthritis (axSpA) with biologic disease-modifying antirheumatic drugs (bDMARD) and targeted synthetic DMARDs (tsDMARD), according to current evidence and expert opinion. Materials and Methods: The development process involved 46 rheumatologist representatives from medical schools, government hospitals, and private hospitals nationwide. Relevant clinical questions related to treatment initiation criteria, administration, evaluation, monitoring, and intensive treatment options were selected. The evidence was systematically identified and summarized. Quality of evidence was evaluated and ranked according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) scoring methodology. The recommendations were then proposed and voted on using the nominal group process. The input was collected from stakeholders through a public hearing. The final 13 recommendations were provided. Results: The guideline addresses the criteria for starting bDMARD/tsDMARD and details the first-line drugs for specific disease profiles, including predominantly axial involvement, predominantly peripheral joint involvement, and uveitis. It also addresses the management of patients with comorbid conditions such as tuberculosis, chronic hepatitis B, malignancy, and pregnancy. Additionally, it covers monitoring and follow-up procedures, alternative treatments for first-line treatment failures, tapering treatment after remission, and reinstitution of bDMARD/tsDMARD in case of flare-up. Conclusion: Thai Rheumatism Association has proposed a set of recommendations to outline concepts and provide guidance on the treatment of axSpA with bDMARD and tsDMARD for Thai rheumatologists.
KW - Axial spondyloarthritis
KW - Biologic disease-modifying antirheumatic drug
KW - Monitoring
KW - Targeted synthetic disease-modifying antirheumatic drug Treatment
UR - https://www.scopus.com/pages/publications/105007290062
U2 - 10.35755/jmedassocthai.2024.11.930-944-01586
DO - 10.35755/jmedassocthai.2024.11.930-944-01586
M3 - Article
AN - SCOPUS:105007290062
SN - 0125-2208
VL - 107
SP - 930
EP - 944
JO - Journal of the Medical Association of Thailand
JF - Journal of the Medical Association of Thailand
IS - 11
ER -